The company will likely see a steady rise in revenue led by continued market share gains for its drugs – Darzalex, Stelara, and Tremfya. The pharmaceutical sales growth over the recent quarters has been led by market share gains for Stelara, Tremfya, and Darzalex, a trend expected to continue in the near term. While the company sees continued sales growth, the operating margins are expected to face headwinds from inflationary pressure and increased marketing expenses.